Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.33    -0.01 (-0.43%)
Bid:
2.32
Ask:
2.35
Spread: 0.03 (1.293%)
Market Cap: $752.76m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Quarterly Update

17 Apr 2020 07:00

RNS Number : 9552J
RTW Venture Fund Limited
17 April 2020
 

LEI: 549300Q7EXQQH6KF7Z84

17 April 2020

RTW Venture Fund Limited

Quarterly Update

RTW Venture Fund Limited (the "Company") is pleased to announce that the Fact Sheet for the quarter ended 31 March 2020 is now available on its website www.rtwfunds.com.

For Further Information

RTW Investments, LP +1 (646) 343 9280Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

 

Ocorian (Company Secretary) +44 (0)1481 742 642Kevin Smith

 

J.P. Morgan Cazenove +44 (0)20 7742 4000

William Simmonds

Oliver Kenyon

James Bouverat (Sales)

 

Barclays +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

Alwyn Clarke

Ryan McCarthy

 

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBCGDSGXBDGGL
Date   Source Headline
1st Nov 20242:00 pmRNSNew Investment in Series C Round of Evommune, Inc.
1st Nov 20247:00 amRNSRTW Biotech Opportunities’ 5th Anniversary
14th Oct 20246:12 pmRNSMonthly Valuation Update and Factsheet Replacement
14th Oct 20247:00 amRNSMonthly Valuation Update and Factsheet
3rd Oct 20247:00 amRNSLaunch of Obesity Company Kailera Therapeutics
2nd Oct 20247:00 amRNSNew Investment in Aktis Oncology
27th Sep 20247:00 amRNSBioAge Labs completes $198 million IPO
26th Sep 20247:00 amRNSGBP quote for the share class to cease
16th Sep 20247:00 amRNSMonthly Valuation Update and Factsheet
13th Sep 20247:00 amRNSHalf-year Report
14th Aug 20247:01 amRNSClosed Period Notification
14th Aug 20247:00 amRNSMonthly Valuation Update and Factsheet
6th Aug 20247:00 amRNSNew Investment in Jade Biosciences, Inc
22nd Jul 202412:00 pmRNSArtiva Biotherapeutics prices IPO at $167 million
15th Jul 20247:00 amRNSMonthly Valuation Update and Factsheet
11th Jul 20247:00 amRNSBaroness Blackwood Appointed as Independent NED
2nd Jul 20247:00 amRNSInvestment in Mirador Therapeutics & Santa Ana Bio
1st Jul 20247:00 amRNSTotal Voting Rights
14th Jun 20247:00 amRNSMonthly Valuation Update and Factsheet
13th Jun 20247:00 amRNSPositive Data Announcement - Avidity Biosciences
11th Jun 20247:00 amRNSPortfolio Company Numab Therapeutics Update
5th Jun 20247:00 amRNSTransaction in Own Shares
3rd Jun 20247:00 amRNSTotal Voting Rights
31st May 202412:00 pmRNSDirector Declaration
31st May 20247:00 amRNSTransaction in Own Shares
29th May 20247:00 amRNSHolding(s) in Company
28th May 20247:00 amRNSHolding(s) in Company
24th May 202412:00 pmRNSCancellation of Own Shares
16th May 20244:47 pmRNSResult of AGM
15th May 20247:01 amRNSTransaction in Own Shares
15th May 20247:00 amRNSAdditional Investment in Lycia Therapeutics
14th May 20247:00 amRNSMonthly Valuation Update and Factsheet
1st May 20247:01 amRNSTotal Voting Rights
1st May 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20244:46 pmRNSAnnual Financial Report
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20249:30 amRNSNotice of AGM
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSMonthly Valuation Update and First Quarter Letter
12th Apr 20245:42 pmRNSPortfolio Company Update: Artios Pharma
12th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 202410:00 amRNSNew Investment: Obsidian Therapeutics
5th Apr 20247:01 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20247:01 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.